Michael S Leong, MD
Pain Management · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Leong’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A53960 · Current
Licensed to practise in California · since 1995 · expires 2026-12-31 · Georgetown University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$59,311
Medicare paid this office $59,311 for 395 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 103 | $13,055 | $99 |
| New patient visit (60+ min) | 57 | $9,977 | $175 |
| Long return visit (40+ min) | 37 | $5,911 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $5,636 | $70 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 57 | $3,929 | $69 |
See all 9 services
| Return visit (30+ min) | 103 | $13,055 | $99 |
| New patient visit (60+ min) | 57 | $9,977 | $175 |
| Long return visit (40+ min) | 37 | $5,911 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $5,636 | $70 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 57 | $3,929 | $69 |
| New patient visit (60+ min) | 22 | $3,350 | $152 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,520 | $117 |
| Injection of trigger points, 3 or more muscles | 15 | $564 | $38 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 17 | $166 | $9 |
Who their Medicare patients are
395 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 13% · Women 64% · Also on Medicaid 26% · Health risk score 1.62. Above the middle of the specialty; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 70% · Depression 33% · Diabetes 29% · Coronary heart disease 29% · Chronic kidney disease 26% · Cancer 21% · Atrial fibrillation 20% · Heart failure 19% · COPD 13% · Stroke 9% · Dementia 8%.
The office billed $647,612, Medicare allowed $77,914 and paid $59,311; for 608 services of 52 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 395 | 608 | 73 | 1.62 | $647,612 | $59,311 |
| 2023 | 501 | 928 | 72 | 1.81 | $910,214 | $83,095 |
| 2022 | 557 | 1,046 | 69 | 1.77 | $1,087,576 | $83,233 |
| 2021 | 458 | 948 | 69 | 1.97 | $767,004 | $80,065 |
| 2020 | 521 | 1,159 | 69 | 1.87 | $879,312 | $95,443 |
| 2019 | 533 | 1,040 | 70 | 1.67 | $636,215 | $86,267 |
| 2018 | 472 | 902 | 69 | 1.77 | $486,978 | $74,144 |
| 2017 | 403 | 826 | 69 | 1.57 | $469,159 | $72,123 |
| 2016 | 632 | 1,383 | 69 | 1.72 | $859,950 | $112,041 |
| 2015 | 507 | 1,039 | 68 | 1.78 | $627,793 | $78,741 |
| 2014 | 720 | 1,342 | 68 | 1.56 | $487,640 | $93,163 |
| 2013 | 540 | 1,083 | 68 | 1.59 | $435,645 | $80,244 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 107 | $14,617 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 99 | $12,695 | $73 |
| Return visit (30+ min) | 60 | $6,274 | $83 |
| New patient visit (60+ min) | 35 | $5,682 | $162 |
| Long return visit (40+ min) | 39 | $5,313 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $3,401 | $110 |
| Long return visit (40+ min) | 24 | $3,325 | $133 |
| New patient visit (60+ min) | 20 | $2,935 | $147 |
| Daily hospital management of continuous spinal drug administration | 20 | $2,034 | $55 |
| Return visit (30+ min) | 19 | $1,951 | $89 |
| Injection of substance into lower spine canal using imaging guidance | 19 | $1,561 | $78 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 12 | $1,432 | $110 |
| Injection of trigger points, 3 or more muscles | 33 | $1,351 | $37 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 12 | $788 | $61 |
| Injection of trigger points, 1-2 muscles | 12 | $474 | $32 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 42 | $202 | $4 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 21 | $95 | $4 |
2022: 15 services
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 165 | $15,856 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 150 | $15,422 | $63 |
| Long return visit (40+ min) | 38 | $6,002 | $118 |
| New patient visit (60+ min) | 36 | $5,177 | $144 |
| Return visit (30+ min) | 53 | $4,564 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,296 | $91 |
| Long return visit (40+ min) | 19 | $2,366 | $125 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 19 | $2,056 | $103 |
| Injection of substance into lower spine canal using imaging guidance | 25 | $1,982 | $79 |
| Daily hospital management of continuous spinal drug administration | 15 | $1,180 | $49 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 19 | $1,101 | $55 |
| Injection of trigger points, 3 or more muscles | 14 | $544 | $36 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 65 | $319 | $4 |
| Fluoroscopic guidance for needle placement | 12 | $275 | $23 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 15 | $72 | $4 |
2021: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 151 | $17,726 | $66 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 136 | $14,466 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $9,069 | $95 |
| Return visit (30+ min) | 32 | $3,032 | $87 |
| Long return visit (40+ min) | 23 | $3,031 | $126 |
| New patient visit (60+ min) | 13 | $2,188 | $168 |
| New patient visit (60+ min) | 13 | $2,064 | $159 |
| Daily hospital management of continuous spinal drug administration | 15 | $1,785 | $54 |
| Injection of substance into lower spine canal using imaging guidance | 11 | $1,025 | $79 |
| Injection of trigger points, 3 or more muscles | 19 | $809 | $39 |
| Ultrasonic guidance for needle placement | 26 | $758 | $27 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 30 | $347 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $115 | $10 |
2020: 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 168 | $18,697 | $67 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 180 | $18,297 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $5,927 | $97 |
| Return visit (30+ min) | 69 | $5,853 | $71 |
| New patient visit (60+ min) | 28 | $4,154 | $148 |
| Long return visit (40+ min) | 35 | $3,501 | $97 |
| New patient visit (45+ min) | 27 | $3,180 | $118 |
| Daily hospital management of continuous spinal drug administration | 19 | $1,933 | $57 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 11 | $1,417 | $118 |
| Short return visit (20+ min) | 16 | $793 | $47 |
| Ultrasonic guidance for needle placement | 24 | $670 | $28 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 14 | $596 | $43 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 43 | $526 | $11 |
| Injection of trigger points, 3 or more muscles | 13 | $487 | $35 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 15 | $226 | $11 |
2019: 19 services
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 157 | $15,454 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 136 | $12,668 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $6,104 | $94 |
| Return visit (30+ min) | 54 | $4,784 | $68 |
| New patient visit (45+ min) | 35 | $3,784 | $108 |
| New patient visit (60+ min) | 25 | $3,616 | $145 |
| Return visit (30+ min) | 42 | $2,769 | $63 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 11 | $2,369 | $215 |
| Long return visit (40+ min) | 22 | $2,327 | $93 |
| Long return visit (40+ min) | 23 | $2,008 | $87 |
| Injection of substance into lower spine canal using imaging guidance | 17 | $1,787 | $105 |
| New patient visit (60+ min) | 12 | $1,680 | $140 |
| Daily hospital management of continuous spinal drug administration | 17 | $1,671 | $52 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 11 | $1,187 | $99 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 11 | $679 | $57 |
| Ultrasonic guidance for needle placement | 15 | $435 | $29 |
| Injection of trigger points, 3 or more muscles | 11 | $397 | $36 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 35 | $396 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 22 | $311 | $11 |
2018: 13 services
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 120 | $11,228 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 111 | $10,851 | $65 |
| Return visit (30+ min) | 99 | $7,999 | $62 |
| New patient visit (45+ min) | 42 | $4,297 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,745 | $94 |
| New patient visit (60+ min) | 26 | $3,394 | $131 |
| Long return visit (40+ min) | 32 | $3,172 | $99 |
| New patient visit (45+ min) | 16 | $1,844 | $115 |
| Return visit (30+ min) | 20 | $1,554 | $71 |
| Daily hospital management of continuous spinal drug administration | 13 | $1,017 | $57 |
| Short return visit (20+ min) | 13 | $595 | $46 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 23 | $319 | $13 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 21 | $258 | $11 |
2017: 12 services
| Return visit (30+ min) | 102 | $10,452 | $71 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 93 | $9,325 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 86 | $8,227 | $65 |
| New patient visit (45+ min) | 53 | $6,373 | $120 |
| New patient visit (60+ min) | 43 | $6,338 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $3,833 | $93 |
| Long return visit (40+ min) | 26 | $3,081 | $99 |
| Daily hospital management of continuous spinal drug administration | 17 | $1,630 | $56 |
| Short return visit (20+ min) | 15 | $798 | $47 |
| Ultrasonic guidance for needle placement | 12 | $348 | $29 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 26 | $293 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 16 | $218 | $11 |
2016: 18 services
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 192 | $18,736 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 157 | $13,760 | $64 |
| Return visit (30+ min) | 98 | $10,072 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $8,241 | $93 |
| New patient visit (60+ min) | 55 | $8,059 | $147 |
| Daily hospital management of continuous spinal drug administration | 62 | $7,417 | $56 |
| Long return visit (40+ min) | 29 | $3,112 | $94 |
| New patient visit (45+ min) | 25 | $3,022 | $121 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,704 | $180 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 58 | $2,287 | $38 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $2,065 | $121 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,459 | $97 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 31 | $1,453 | $37 |
| Injections of substances into lower or sacral spine | 12 | $1,160 | $83 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 11 | $1,104 | $100 |
| Short return visit (20+ min) | 15 | $638 | $43 |
| Ultrasonic guidance for needle placement | 18 | $570 | $30 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 12 | $509 | $42 |
2015: 18 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 125 | $11,460 | $65 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 109 | $10,680 | $90 |
| Daily hospital management of continuous spinal drug administration | 55 | $6,763 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $5,835 | $93 |
| New patient visit (60+ min) | 31 | $4,638 | $150 |
| Return visit (30+ min) | 64 | $4,427 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,438 | $122 |
| New patient visit (45+ min) | 21 | $2,425 | $115 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 52 | $2,066 | $37 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,012 | $168 |
| Long return visit (40+ min) | 14 | $1,392 | $99 |
| Return visit (30+ min) | 17 | $1,196 | $70 |
| Short return visit (20+ min) | 41 | $1,173 | $27 |
| Injections of substances into lower or sacral spine | 14 | $1,159 | $83 |
| Ultrasonic guidance for needle placement | 22 | $670 | $29 |
| Injection of trigger points, 3 or more muscles | 12 | $453 | $35 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $383 | $32 |
| Fluoroscopic guidance for spine or back muscle injection | 11 | $273 | $25 |
2014: 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 196 | $16,935 | $63 |
| Return visit (30+ min) | 142 | $12,849 | $66 |
| Daily hospital management of continuous spinal drug administration | 89 | $8,570 | $57 |
| Short return visit (20+ min) | 140 | $8,486 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $8,318 | $92 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 88 | $7,945 | $89 |
| New patient visit (60+ min) | 22 | $3,179 | $144 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,556 | $122 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,158 | $180 |
| Long return visit (40+ min) | 21 | $2,156 | $98 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 39 | $1,654 | $38 |
| New patient visit (45+ min) | 12 | $1,264 | $105 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 26 | $902 | $35 |
| Ultrasonic guidance for needle placement | 21 | $659 | $30 |
| Fluoroscopic guidance for spine or back muscle injection | 15 | $382 | $25 |
2013: 11 services
| Return visit (30+ min) | 150 | $15,460 | $64 |
| Daily hospital management of continuous spinal drug administration | 152 | $14,925 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $8,995 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,475 | $174 |
| New patient visit (60+ min) | 42 | $5,895 | $140 |
| Short return visit (20+ min) | 90 | $4,722 | $41 |
| Long return visit (40+ min) | 26 | $2,367 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $2,361 | $62 |
| New patient visit (45+ min) | 24 | $2,202 | $92 |
| Injections of substances into lower or sacral spine | 19 | $1,596 | $80 |
| Fluoroscopic guidance for spine or back muscle injection | 26 | $731 | $27 |
Medicaid work
$930 in 2024
Medicaid paid $930 for 30 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 12 | $674 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 18 | $257 |
| 2024 | 30 | 2 | 15 | $930 |
| 2023 | 33 | 2 | 15 | $1,111 |
| 2022 | 87 | 1 | 15 | $2,523 |
| 2021 | 167 | 2 | 19 | $4,962 |
| 2020 | 141 | 3 | 19 | $4,440 |
| 2019 | 35 | 1 | 13 | $600 |
| 2018 | 20 | 1 | 12 | $443 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 21 | $601 |
| Return visit (30+ min) | 12 | $510 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 87 | $2,523 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 100 | $3,374 |
| 1ST HOSP IP/OBS SF/LOW 40 | 67 | $1,588 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 105 | $3,384 |
| IP/OBS CONSLTJ NEW/EST PT LOW MDM 45 MINUTES | 14 | $619 |
| 1ST HOSP IP/OBS SF/LOW 40 | 22 | $437 |
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 35 | $600 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 20 | $443 |
Drugs they prescribed that Part D paid
$6,298
Pharmacies billed $6,298 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
165 generic and fewer than 11 brand-name prescriptions · $6,298 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gabapentin | 56 | $965 | $17 |
| Baclofen | 17 | $956 | $56 |
| Pregabalin | 32 | $607 | $19 |
| Duloxetine | 17 | $287 | $17 |
Year by year
| 2024 | 166 | 54 | None | None | $6,298 |
| 2023 | 142 | 55 | None | None | $11,406 |
| 2022 | 100 | 39 | None | None | $8,954 |
| 2021 | 79 | 29 | None | None | $7,324 |
| 2020 | 144 | 50 | None | 11% | $12,931 |
| 2019 | 223 | 59 | 5% (11) | 13% | $20,049 |
| 2018 | 322 | 83 | 9% (28) | 14% | $30,882 |
| 2017 | 262 | 90 | 20% (52) | 17% | $26,217 |
| 2016 | 304 | 79 | 14% (41) | 18% | $29,945 |
| 2015 | 250 | 74 | 15% (38) | 22% | $17,961 |
| 2014 | 265 | 87 | 17% (44) | 26% | $35,387 |
| 2013 | 529 | 97 | 11% (59) | 15% | $29,915 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Baclofen | 21 | $1,416 | $67 |
| Gabapentin | 42 | $1,412 | $34 |
| Pregabalin | 22 | $1,039 | $47 |
| Duloxetine | 24 | $962 | $40 |
2022: 3 drugs
| Gabapentin | 34 | $1,800 | $53 |
| Tizanidine | 11 | $685 | $62 |
| Baclofen | 12 | $595 | $50 |
2021: 2 drugs
| Gabapentin | 24 | $1,322 | $55 |
| Baclofen | 19 | $302 | $16 |
2020: 5 drugs
| Aimovig | Migraine | 12 | $7,657 | $638 |
| Baclofen | None | 47 | $1,242 | $26 |
| Gabapentin | None | 22 | $758 | $34 |
| Pregabalin | None | 14 | $450 | $32 |
| Nortriptyline | None | 13 | $65 | $5 |
2019: 3 drugs
| Gabapentin | 50 | $1,657 | $33 |
| Baclofen | 57 | $1,238 | $22 |
| Duloxetine | 18 | $846 | $47 |
2018: 9 drugs
| Lyrica | 17 | $13,127 | $772 |
| Carbamazepine Er | 13 | $4,021 | $309 |
| Duloxetine | 43 | $2,956 | $69 |
| Lidocaine | 18 | $1,852 | $103 |
| Gabapentin | 41 | $1,355 | $33 |
| Baclofen | 50 | $1,016 | $20 |
| Voltaren | 16 | $864 | $54 |
| Diclofenac | 11 | $375 | $34 |
| Cyclobenzaprine | 22 | $63 | $3 |
2017: 6 drugs
| Fentanyl | 11 | $1,837 | $167 |
| Duloxetine | 21 | $1,298 | $62 |
| Lidocaine | 12 | $905 | $75 |
| Gabapentin | 39 | $713 | $18 |
| Baclofen | 29 | $551 | $19 |
| Cephalexin | 14 | $106 | $8 |
2016: 6 drugs
| Lyrica | 11 | $6,295 | $572 |
| Duloxetine | 29 | $1,264 | $44 |
| Gabapentin | 38 | $902 | $24 |
| Tizanidine | 11 | $369 | $34 |
| Baclofen | 13 | $266 | $20 |
| Nortriptyline | 19 | $131 | $7 |
2015: 6 drugs
| Duloxetine | 17 | $2,414 | $142 |
| Gabapentin | 53 | $1,273 | $24 |
| Voltaren | 18 | $857 | $48 |
| Quetiapine | 12 | $572 | $48 |
| Nortriptyline | 13 | $115 | $9 |
| Lisinopril | 12 | $80 | $7 |
2014: 6 drugs
| Lyrica | 34 | $14,545 | $428 |
| Duloxetine | 31 | $8,391 | $271 |
| Gabapentin | 41 | $1,746 | $43 |
| Tizanidine | 12 | $905 | $75 |
| Quetiapine | 14 | $758 | $54 |
| Hydrocodone-Acetaminophen | 12 | $294 | $25 |
2013: 15 drugs
| Cymbalta | 16 | $7,801 | $488 |
| Nexium | 13 | $2,820 | $217 |
| Gabapentin | 33 | $1,549 | $47 |
| Hydrocodone-Acetaminophen | 19 | $769 | $40 |
| Simvastatin | 53 | $399 | $8 |
| Methadone | 16 | $327 | $20 |
| Mexiletine | 12 | $297 | $25 |
| Atorvastatin | 15 | $296 | $20 |
| Clopidogrel | 15 | $259 | $17 |
| Metformin | 15 | $198 | $13 |
| Levothyroxine | 17 | $155 | $9 |
| Benazepril | 17 | $154 | $9 |
| Amlodipine Besylate | 16 | $152 | $9 |
| Lisinopril | 19 | $101 | $5 |
| Glipizide | 11 | $100 | $9 |
Money from drug and device companies
$634 in 2025
| 2025 | 2 | 5 | None | $634 |
| 2024 | 7 | 19 | None | $2,075 |
| 2023 | 5 | 16 | None | $1,545 |
| 2022 | 3 | 6 | None | $203 |
| 2021 | 5 | 22 | None | $482 |
| 2020 | 4 | 5 | None | $336 |
| 2019 | 6 | 21 | $675 | $2,069 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotronik Nro | Prospera | $509 | 3 payments
|
| Si-Bone | None | $125 | 2 payments
|
See all 5 published payments
| Biotronik Nro | Meals · 2025-09-18 | Prospera | $149 |
| Biotronik Nro | Meals · 2025-07-18 | Prospera | $142 |
| Si-Bone | Meals · 2025-03-21 | None | $39 |
| Biotronik Nro | Meals · 2025-02-26 | Prospera | $218 |
| Si-Bone | Meals · 2025-02-07 | None | $87 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,075
| Mml US | Reactiv8 | $958 | 6 payments
|
| Painteq | Painteq | $452 | 6 payments
|
| Abbott Laboratories | Eterna | $298 | 2 payments
|
| Biotronik Nro | Prospera | $185 | 2 payments
|
| SPR Therapeutics | Sprint Pns System | $81 | 1 payment
|
| Saluda Medical Americas | Evoke | $81 | 1 payment
|
| Pacira Pharmaceuticals | Exparel | $20 | 1 payment
|
2023: $1,545
| Boston Scientific | Wavewriter Alpha Prime 16 | $774 | 8 payments
|
| Biotronik Nro | Biotronik | $310 | 2 payments
|
| Painteq | Painteq | $297 | 3 payments
|
| Nevro | Senza | $158 | 2 payments
|
| Saluda Medical Americas | Evoke Scs | $6 | 1 payment
|
2022: $203
| Biogen | Spinraza | $124 | 1 payment
|
| Abbott Laboratories | Proclaim | $63 | 3 payments
|
| Stimwave Technologies | Stimq Receiver Stimulator Kit Channel A US W/Receiver | $15 | 2 payments
|
2021: $482
| Abbott Laboratories | Proclaim Ipg | $290 | 16 payments
|
| Stimwave Technologies | Stimq Receiver Stimulator Kit Channel A US W Receiver | $62 | 1 payment
|
| Painteq | Painteq | $44 | 1 payment
|
| Relievant Medsystems | Intracept | $44 | 2 payments
|
| Boston Scientific | Superion | $41 | 2 payments
|
2020: $336
| Abbott Laboratories | Prodigy Family of Scs Ipgs | $134 | 1 payment
|
| Nalu Medical | Nalu Neurostimulation System | $100 | 2 payments
|
| Si-Bone | Ifuse Implant | $87 | 1 payment
|
| Nevro | Senza Spinal Cord Stimulation System | $15 | 1 payment
|
2019: $2,069
| Bioness | Stimrouter for Pain | $747 | 2 payments
|
| Vertos Medical | Mild Device Kit | $675 | 1 payment
|
| Nevro | Senza Spinal Cord Stimulation System | $349 | 9 payments
|
| Abbott Laboratories | Prodigy Family of Scs Ipgs | $185 | 3 payments
|
| Vertiflex | Superion Iss | $74 | 2 payments
|
| TerSera Therapeutics | Prialt | $39 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Efficacy and Safety of Vx-150 in Treating Subjects With Pain Caused By Small Fiber Neuropathy · 2019 | Their institution | $9,756 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1316073109
- Licence
- CA A53960California A53960: Current · expires 2026-12-31
- Trained
- Georgetown University School of Medicine, 1993
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207LP2900X (207LP2900X); Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 1804 Embarcadero Rd, Suite 100, Palo Alto, CA, 94303
- NPI first listed
- 2007-02-26
- NPI last updated
- 2024-04-11
- NPI record certified
- 2024-04-11
This is when the NPI record was last certified, not a medical board exam.